QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: mol.109.054825v1 75/6/1412    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Flaveny, C. A. Articles by Perdew, G. H. PubMed PubMed Citation Articles by Flaveny, C. A. Articles by Perdew, G. H.

Ligand Selectivity and Gene Regulation by the Human Aryl Hydrocarbon Receptor in Transgenic Mice

Center for Molecular Toxicology and Carcinogenesis and the Department of Veterinary and Biomedical Sciences, the Pennsylvania State University, University Park, Pennsylvania

The aryl hydrocarbon receptor (AHR) is a ligand-inducible transcription factor that displays interspecies differences with the human and mouse AHR C-terminal region sequences sharing only 58% amino acid sequence identity. Compared with the mouse AHR (mAHR), the human AHR (hAHR) displays 10-fold lower relative affinity for prototypical AHR ligands such as 2,3,7,8-tetrachlorodibenzo-p-dioxin, which has been attributed to the amino acid residue valine 381 (alanine 375 in the mAHR) in the ligand binding domain of the hAHR. We investigated whether the 10-fold difference in ligand-binding affinity between the mAHR and hAHR would be observed with a diverse range of AHR ligands. To test this hypothesis, ligand binding assays were performed using the photo-affinity ligand 2-azido-3-[¹²⁵I]iodo-7,8-dibromodibenzo-p-dioxin and liver cytosol isolated from hepatocyte-specific transgenic hAHR mice and C57BL/6J mice. It is noteworthy that competitive ligand-binding assays revealed that, compared with the mAHR, the hAHR has a higher relative affinity for certain compounds, including indirubin [(2Z)-2,3-biindole-2,3 (1'H,1'H)-dione and quercetin (2-(3,4dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one]. Electrophoretic mobility shift assays revealed that indirubin was more efficient at transforming the hAHR compared with the mAHR. Indirubin was also a more potent inducer of Cyp1a1 expression in transgenic hAHR mouse hepatocytes compared with C57BL/6J mouse hepatocytes. These observations suggest that indirubin is a potent hAHR ligand that is able to selectively bind to and activate the hAHR. These discoveries imply that there may be a significant degree of structural divergence between mAHR and hAHR ligands and highlights the importance of the hAHR transgenic mouse as a model to study the hAHR in vivo.

Received for publication January 15, 2009.

Accepted for publication March 19, 2009.

Address correspondence to: Dr. Gary H. Perdew, Center for Molecular Toxicology and Carcinogenesis, Department of Veterinary Science, Pennsylvania State University, 309A Life Sciences Building, University Park, PA 16802. E-mail: ghp2{at}psu.edu

This article has been cited by other articles:

				E. A. Carlson, C. McCulloch, A. Koganti, S. B. Goodwin, T. R. Sutter, and J. B. Silkworth Divergent Transcriptomic Responses to Aryl Hydrocarbon Receptor Agonists between Rat and Human Primary Hepatocytes Toxicol. Sci., November 1, 2009; 112(1): 257 - 272. [Abstract] [Full Text] [PDF]

				O. Hankinson Repression of Aryl Hydrocarbon Receptor Transcriptional Activity by Epidermal Growth Factor Mol. Interv., June 1, 2009; 9(3): 116 - 118. [Abstract] [Full Text] [PDF]